Cargando…
A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-release HydromorphonE for cAncer pain reLief)
BACKGROUND: In Japan, there are limited options for switching opioid analgesics. Hydromorphone is an opioid analgesic that is routinely used instead of morphine for cancer pain; however, it is not yet available in Japan. The aim of this study was to assess the efficacy and safety of hydromorphone (D...
Autores principales: | Inoue, Satoshi, Saito, Yoji, Tsuneto, Satoru, Aruga, Etsuko, Ide, Azusa, Kakurai, Yasuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571837/ https://www.ncbi.nlm.nih.gov/pubmed/28860850 http://dx.doi.org/10.2147/JPR.S136937 |
Ejemplares similares
-
A randomized, double-blind, non-inferiority study of hydromorphone hydrochloride immediate-release tablets versus oxycodone hydrochloride immediate-release powder for cancer pain: efficacy and safety in Japanese cancer patients
por: Inoue, Satoshi, et al.
Publicado: (2018) -
A new extended release formulation (OROS(®)) of hydromorphone in the management of pain
por: Weinstein, Sharon M
Publicado: (2009) -
Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain
por: Vandenbossche, Joris, et al.
Publicado: (2012) -
Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009) -
Effects of oxycodone hydrochloride sustained-release tablets and morphine hydrochloride sustained-release tablets on peripheral blood T cell levels in advanced lung squamous cell carcinoma with moderate to severe cancer pain
por: Yan, Juan, et al.
Publicado: (2023)